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http://www.lipidworld.com/content/12/1/41RESEARCH Open AccessRosiglitazone and bezafibrate modulate gene
expression in a rat model of non-alcoholic fatty
liver disease - A historical prospective
Hemda Schmilovitz-Weiss1,2*†, Edith Hochhauser3†, Michal Cohen2, Yelena Chepurko3, Smadar Yitzhaki4,
Ehud Grossman5, Avshalom Leibowitz5, Zvi Ackerman6 and Ziv Ben-Ari1,2Abstract
Background: Genetic factors implicated in the pathogenesis of non-alcoholic fatty liver disease are poorly
understood. Our aim was to characterize three genes involved in a rat model of non-alcoholic fatty liver disease
and investigate the effect of rosiglitazone and bezafibrate.
Method: Five rats were fed a chow diet (controls) and 18 a fructose-enriched diet (FED) for 5 weeks: 6 were
administered rosiglitazone and 6 bezafibrate during the last 2 weeks and 6 were not treated at all. Livers were
examined by reverse transcription-PCR for the genes encoding peroxisome proliferator-activated receptors (PPAR),
PPAR-α, PPAR-γ, and Mn superoxide dismutase2 (Mn SOD2). Western blot was used for proteins levels.
Result: The FED rats showed a decrease in mRNA of MnSOD2, PPAR-α, and PPAR-γ (3, 3.5 fold, and 27%,
respectively) (p<0.05). The 3 genes normalized in response to rosiglitazone and bezafibrate. The proteins of
MnSOD2, PPAR-α and PPAR-γ in the FED rats decreased (2.5, 2, and 2.2, respectively) (p<0.05). Following
administration of rosiglitazone, proteins of MnSOD2, PPAR-α and PPAR-γ in the FED rats increased (reaching 1.5-
fold, a 20% increase and normalization, respectively), (p<0.05). Administration of bezafibrate to the FED rats restored
the proteins of 3 genes to baseline.
Conclusion: A consistent reduction in hepatic expression of MnSOD2, PPAR-α and PPAR-γ in the FED rats
compared with controls was observed. Administration of either rosiglitazone or bezafibrate to the FED rats restored
these genes to a pre-morbid state.
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Nonalcoholic fatty liver disease (NAFLD) is considered
the hepatic manifestation of the metabolic syndrome
[1]. The clinical spectrum of NAFLD ranges from
simple steatosis to steatohepatitis, bridging fibrosis, and
cirrhosis [2]. The primary event of NAFLD is the accu-
mulation of triglycerides in hepatocytes which appear to
be determined by insulin resistance [3]. The secondary* Correspondence: hemdaw1@netvision.net.il
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distribution, and reproduction in any mediumevent is hepatocellular injury (nonalcoholic steatohepatitis -
NASH) involving factors such as oxidative stress, increased
proinflammatory cytokines, mitochondrial dysfunction, iron
overload, bacterial overgrowth and genetic predisposition
[4]. Although metabolic risk factors for NAFLD progression
are well known, the role of genetic susceptibility remains
unclear [5-7].
Recent studies have implicated the nuclear hormones
peroxisome proliferator-activated receptors (PPARs),
PPAR-α and PPAR-γ in the pathogenesis of NAFLD
[8-12]. PPAR-α reduces liver fat by increasing β-oxidation
of fatty acids. PPAR-γ increases insulin sensitivity, thus
reducing fatty acid flux to the liver. Accordingly, PPAR
ligands have shown promise in the treatment of
NAFLD [13-26].ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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[8,11,13-16,18,19]. Fibrates such as bezafibrate exert
their effects by activating PPAR-α [8-26]. The oxidative
stress induced by steatosis is counteracted by cellular en-
zymatic and nonenzymatic antioxidant systems. The cyto-
solic and mitochondrial superoxide dismutases (SODs), in
addition to glutathione peroxidase and catalase, eliminate
the reactive oxygen species (ROS) formed during the fatty
acid oxidation process [27].
Non-obese rats fed a fructose-enriched diet (FED) have
been found to acquire histologically-proven NAFLD and
also exhibit certain aspects of the metabolic syndrome,
such as hypertension, insulin resistance, and hyper-
triglyceridemia [28].
In this study, samples archived from previous studies
from 2005 [28] and 2007 were analyzed [29]. Changes in
plasma and hepatic triglycerides and phospholipids have
been previously published in response to administration of
rosiglitazone and bezafibrate [28,29]. Histological changes
were assessed by modifying the scoring system of the
grading and staging of non-alcoholic steatohepatitis as
described by Brunt et al. [30]. The histological evaluation
of the liver sections was blindly performed [29].
The livers of the control group (rats fed with a standard
rat chow diet, Koffolk) showed no signs of macrovesicular
steatosis or fibrosis. The livers of the FED rats showed
mild to moderate macrovesicular and microvesicular fat
with minimal signs of perisinusoidal fibrosis.
The FED rats had 188% higher plasma triglyceride levels
compared to the control group. Changes in liver enzymes
were not observed between groups, however, the ratio of
alanine to aspartate aminotransferase which was 1.2:1.0 in
the control group increased to 2.0:1.0 in the FED rats. The
livers of the FED rats had higher concentrations of total
lipids (+28%), triglycerides (+198%), and cholesterol
(+89%), but lower concentrations of phospholipids (−36%)
compared to the livers of the control rats.
Administration of rosiglitazone to the FED rats was
associated with decreases in plasma triglycerides (−62%),
hepatic total lipids (−19%), hepatic triglycerides
(−61%), and increases in hepatic phospholipids (+46%).
Administration of rosiglitazone to the FED rats initiated
a decrease in the hepatic macrovesicular steatosis score
without an improvement in the relative fibrosis area [29]
Administration of bezafibrate caused a reduction in
plasma (−49%) and hepatic (−78%) triglycerides concen-
trations and an increase in hepatic phospholipids (+41%)
[28]. Administration of bezafibrate resulted in a significant
reduction in the hepatic macrovesicular steatosis but no
change in the microvesicular steatosis, inflammatory, or
fibrosis score [28].
The aim of this study was to characterize the expression
of principle genes encoding enzymes involved in fatty acid
metabolism (MnSOD2, PPAR-α and PPAR-γ) in a ratmodel of NAFLD and record the changes in their levels
following administration of either rosiglitazone or
bezafibrate.
Material and methods
Animals and experimental protocol
This study was performed on 23 male Sprague–Dawley
rats (Harlan Laboratories Ltd., Jerusalem, Israel) weighing
200–280 grams, housed in regular cages, situated in an
animal room at 22°C and maintained on a 14-hour light/
10-hour dark cycle. The rats were randomly divided into 4
groups. One group, serving as controls, (n=5) was
maintained on a standard rat chow diet for 5 weeks
(Koffolk, Tel Aviv, Israel) with tap water ad libitum. The
other 3 groups (6 rats in each) were given FED for 5
weeks. Three weeks after commencement of FED, one
FED group was also given rosiglitazone (10 mg /kg/day)
and another group, bezafibrate (10 mg/kg/day), for an
additional 2 weeks. Drugs were administered via the
drinking water.
All rats were sacrificed after 5 weeks and their livers
excised for laboratory analysis. All animal studies were
conducted according to the regulations for the use and
care of experimental animals (National Institutes of
Health Guidelines, USA). Our study used archived speci-
mens from previously conducted studies from 2005 [28]
and 2007 [29]. Upon termination of each experiment
(animals sacrifice), liver samples of the rats were cut into
small sized sections to be preserved either as frozen ma-
terial (−70°C) or in formalin and as paraffin embedded
slices. None of the frozen liver specimens had been
subjected to thawing and refreezing. These specimens
were still viable for analysis through molecular biology
techniques.
All rats were sacrificed after 5 weeks and their livers
excised for laboratory analysis. All experiments were car-
ried out in accordance with the guidelines of the Animal
Care and Use Committee of the Chaim Sheba Medical
Center, Israel
Western blot analysis of protein expression
Liver tissue samples (20 mg per sample) from the 23 rats
were homogenized in a lysis buffer and quantified for
protein levels using a commercial assay (Bio-Rad, USA).
Proteins (50 μg/sample) were separated using SDS-
polyacrylamide gels (12.5%) under denaturing conditions
and electrotransferred onto nitrocellulose Bio-Rad) for
1 hour at 100 V.
Membranes were blocked with 5% nonfat milk in a tris-
buffered saline (TBS) containing 0.1% tween 20 (TBST).
The primary antibodies, anti-PPAR-γ, anti-PPAR-α, anti-
SOD (Santa Cruz Biotechnology, Santa Cruz, CA), and
anti-β-actin (Sigma, St. Louis, MO) were diluted 1:1000 in
TBST with 5% nonfat milk and left overnight at 4°C. After
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the secondary antibody for 30 to 60 minutes, as appropri-
ate. Immunodetection and optical density measurement of
the appropriately sized bands were performed using the
Odyssey infrared imaging system (LI-COR Biosciences,
Cambridge, UK).Quantitative reverse-transcriptase polymerase chain
reaction (RT-PCR)
RNA was isolated from the rat livers by mechanical
homogenization and extraction in TRIzol. Reverse tran-
scription was performed using the Applied Biosystems
High Capacity cDNA Reverse Transcription Kit (Kit
4374966; Ambion/Applied Biosystems, Austin, TX, USA).
cDNA concentrations were determined with a Nanodrop
spectro-photometer (Nanodrop Technologies, Wilmington,
DE 19810 United States) followed by absolute quantitative
real-time PCR performed with the 9700HT instrument
(Applied Biosystems, Foster City, CA) set to the default
40-cycle program. TaqMan gene expression assays were
purchased from Applied Biosystems: PPAR-α, Mm0481934;
PPAR-γ, Mm00713303; SOD1 4352932E. Expression
levels were normalized to the TATA box binding protein
(TBP) reference gene (assay Mm00446973_m1). For
each amplicon, PCR efficiency was estimated to be near
1.0 by serial dilutions of cDNA. Relative quantities of
mRNA were estimated using the delta CT method.Setting
The rats were handled at the Hypertension Research
Laboratory of the Chaim Sheba Medical Center, Tel-
Hashomer and their livers were kindly donated by E.
Grossman (co-author) [31]. Z. Ackerman (co-author)
characterized the rats clinically and histopathologically
[28,29]. All experiments were carried out in accord-
ance with the guidelines of the Animal Care and Use
Committee of the Chaim Sheba Medical Center, Israel.
The analyzed samples in the current study were ar-
chived from previous studies from 2005 [28] and 2007
[29]. The stored frozen and formalin fixed liver tissues
were processed for gene expression analysis at the car-
diac and liver Research Laboratory, Felsenstein Medical
Research Center, Petah Tikva, Israel.Statistical analysis
Data are given as means ± standard deviations. Statistically
significant differences in mean values of the variables be-
tween the groups were assessed by one way analysis of
variance (ANOVA). If differences were found, values were
then compared using the Student’s t-test, p < 0.05 was
considered significant.Results
MnSOD2
Hepatic MnSOD2 mRNA expression decreased 3-fold in
the FED rats compared with the rats given standard rat
chow (controls) (p<0.05). The hepatic protein level of
MnSOD2 decreased 2.5-fold compared to the controls
(p<0.05). Following administration of rosiglitazone, gene
expression returned to baseline and protein level
reached a 1.5-fold of baseline (control) level (p<0.05).
MnSOD2 mRNA expression and protein level were
restored to baseline level in the bezafibrate-treated rats
(Figure 1A and 1B).
PPAR-α
Hepatic PPAR-α mRNA expression decreased 3.5-fold in
the FED rats compared with the control levels (p<0.05).
The hepatic PPAR-α protein level, decreased 2-fold
(p<0.05). Administration of rosiglitazone restored both
gene expression and protein level to baseline; bezafibrate
treatment restored both gene expression and protein
level to baseline (control level) (Figure 2A and 2B).
PPAR-γ
Hepatic PPAR-γ mRNA expression decreased by 27% in
the FED rats compared with the controls levels (p<0.05).
Hepatic protein level decreased 2.2-fold. Rosiglitazone
and bezafibrate administration restored gene expression
to baseline. Protein levels reached 20% above the control
levels (p<0.05) in the rosiglitazone treated group and
reached control levels in the bezafibrate-treated rats
(Figure 3A and 3B).
Discussion
The present study demonstrates a statistically signifi-
cant downregulation of hepatic MnSOD2, PPAR-α and
PPAR-γ mRNA expression in FED rats with NAFLD
compared with controls. Following administration of
either rosiglitazone or bezafibrate, the expression of all
three genes normalized. A statistically significant decrease
in hepatic protein levels of all three genes in the FED rats
compared with controls was also demonstrated. Adminis-
tration of both rosiglitazone and bezafibrate to the FED
rats restored to baseline or increased the levels of all three
proteins.
Kohjima et al. [32] reported a reduction in PPAR-α
expression but no change in PPAR-γ expression in
cirrhotic patients with NAFLD.
Earlier studies reported a marked increase in PPAR-γ
expression in fatty livers [20,21] as to the mRNA level and
function of the related protein. Conversely, adipogenesis
resulting in triglyceride storage occurred under conditions
of decreased PPAR-α activity and fatty acid oxidation [22],
implying cross-talk between PPAR-γ and PPAR-α.
Figure 2 Effect of rosiglitazone and bezafibrate on PPAR- α gene expression (A) and protein level (B). * = p<0.05.
Figure 1 Effect of rosiglitazone and bezafibrate on MnSOD2 gene expression (A) and protein level (B). * = p<0.05.
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Figure 3 Effect of rosiglitazone and bezafibrate on PPAR- γ gene expression (A) and protein level (B). * = p<0.05.
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PPAR-α gene expression in mice with hepatic steatosis
under fasting or high-fat diet conditions [10,17] and a
decrease in hepatic steatosis in mice on a methionine- and
choline- deficient diet after administration of a potent
PPAR agonist [8,18,19]. These observations indicate that
in the presence of increased hepatic fatty acid influx or
decreased hepatic fatty acid efflux activation, PPAR-α
prevents accumulation of triglycerides by increasing the
rate of fatty acid catabolism.
Our results are in accordance with Tipoe et al. [33] who
studied rats fed on a high-fat diet, and found significantly
decreased SOD1 and SOD2. This effect was reversed by
pioglitazone co-administration. In contrast, Kohjima et al.
[32] observed a 5-fold increase in SOD expression in
human NAFLD. Sreekumar et al. [34] however, as in the
present study, found a decreased expression of SOD1 in
cirrhotic livers of patients with NASH.
Videla et al. [35] correlated hepatic and plasma oxida-
tive stress-related parameters with clinical and histo-
logical findings in 31 patients with NAFLD, finding that
liver SOD activity decreased in the entire group by 48%
compared with the controls (p<0.05) and by 64% in pa-
tients with steatohepatitis (n=16) (p<0.05). The authors
concluded that oxidative stress develops in the livers of
patients with steatosis and is exacerbated in patients
with steatohepatitis associated with Cytochrome P450 2E1
(CYP2E1) induction. The substantial protein oxidationfollowed by proteolysis of the modified proteins could
account for the coexistence of diminished antioxidant
capacity and protein oxidation in the liver of patients
with steatohepatitis.
Most of the data on PPAR-α and hepatic lipid homeo-
stasis originates from rodent models. There are, how-
ever, important differences in PPAR-α activity between
rodents and humans. PPAR-α DNA binding activity and
PPAR-α expression in human hepatocytes is 10-fold less
than observed in mice [36-38]. In addition, certain PPAR
response elements do not respond to PPAR ligands in
humans as they do in rodent models.
It may be argued that apart from species differences be-
tween human and rodent hepatic genes, the contradictory
results among studies may be explained by differences in
the degree of damage to the fatty liver. Our rats were
sacrificed on the 35th day of the study, and the only overt
histological finding was macrovesicular steatosis which
was mitigated in the treated animals [28,29].
In the present study, administration of either
rosiglitazone or bezafibrate was associated with a
return to baseline level or higher, in all 3 examined
genes. These findings provide evidence for a transcrip-
tional or pre-transcriptional basis of impaired mitochon-
drial function (attenuated capacity for the dismutation of
ROS and diminished insulin sensitivity, reversed by the
insulin sensitizer, rosiglitazone) in rats with NAFLD. Thus,
the post-treatment amelioration of hepatic steatosis in
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restoration of the hepatic gene levels to their pre-morbid
state.
Our study has several limitations. The number of rats in
each group was relatively small. The original experiments
included a larger sample size (controls −11, FED- 10, FED
and rosiglitazone- 9, FED and bezafibrate −10) [28,29],
however, the livers of some of the rats were already spent
for previously described analyses and only 5 or 6 per
group were left for current analyses. Nonetheless, there
were no intra-group significant differences in all
parameters examined, thus strengthening the validity
of our results.
The analyzed samples in the current study were ar-
chived from previous studies. None of the frozen liver
specimens stored in the laboratory had been subjected
to thawing and refreezing. These specimens were still
viable for analysis through molecular biology techniques,
even though they are known for being highly sensitive to
organic degradation. The consistency of the results of
the analyses conducted in our laboratory supports our
confidence in the reliability of the techniques and the
preservation of the frozen tissue.
The results reported in the study relate to one point in
time: termination of the experiment (animals sacrifice).
No liver samples (biopsies) were taken while the animals
were alive. There were no time response or dose response
samples relating to the administration of rosiglitazone or
bezafibrate.
The FED rat model of NAFLD was imperfect because
the rats did not gain weight but nevertheless showed
other basic and prominent characteristics of the meta-
bolic syndrome.
Conclusion
In FED rats with NAFLD, the reduced hepatic expression
might be associated with diminished antioxidant capacity
and alteration of peroxisomal fatty acid metabolism. All
three genes studied are involved in the pathogenesis of
NAFLD. Our results imply that the beneficial therapeutic
effects of PPAR agonists in patients with NAFLD may be
attributed to reversing and normalizing levels of the
relevant hepatic genes.
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